如何认识和理解肺腺癌外科治愈窗口期  

The surgical curative time window for lung adenocarcinoma:A comprehensive understanding

作　　者：傅方求 张扬 陈海泉 FU Fangqiu;ZHANG Yang;CHEN Haiquan(Department of Thoracic Surgery,Cancer Hospital Affiliated to Fudan University,Shanghai,200032,P.R.China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai,200032,P.R.China)

机构地区：[1]复旦大学附属肿瘤医院胸外科,上海200032 [2]复旦大学上海医学院肿瘤学系,上海200032

出　　处：《中国胸心血管外科临床杂志》2023年第12期1674-1677,共4页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：国家自然科学基金重点项目(81930073;82102914)。

摘　　要：近期,Cell Research发表了关于“肺腺癌外科治愈窗口期”的社论,患者在此窗口期内接受手术切除后5年或10年无复发生存率达100.0%。病理学上的原位腺癌和微浸润腺癌及影像学上的纯磨玻璃结节可视为肺腺癌外科治愈窗口期。不是所有肺癌患者均可捕捉到治愈窗口期,正确理解和把握治愈窗口期,不仅可提高治愈率,也能避免过度诊断和过度治疗。本文就如何正确认识和把握肺腺癌外科治愈窗口期,提出早期肺腺癌的临床处理流程,阐明肺腺癌外科治愈窗口期的具体使用方法,为肺腺癌手术时机的选择提供重要理论依据。Recently,an editorial in Cell Research illuminated the concept of the curative time window for lung adenocarcinoma.Within this window,patients could achieve 100.0%5-year or 10-year post-operative recurrence-free survival.Adenocarcinoma in situ and minimally invasive adenocarcinoma in pathology,as well as pure ground-glass opacity in radiology could be regarded as the curative time window.However,not all the patients can catch this time window.A precise understanding of this concept helps elevate the curative rate for lung cancer patients and mitigate the risks of overdiagnosis and overtreatment.This article delves into the accurate comprehension of the surgical curative time window for lung adenocarcinoma,proposed a clinical strategy for early-stage lung adenocarcinoma,and introduced clinical procedures comprising of this time window.It offers fresh insights into the timing of surgical interventions for lung adenocarcinoma.

关 键 词：肺腺癌 手术时机 治愈 磨玻璃结节 述评 

分 类 号：R734.2[医药卫生—肿瘤]